Astellas Pharma Inc
OTC:ALPMY

Watchlist Manager
Astellas Pharma Inc Logo
Astellas Pharma Inc
OTC:ALPMY
Watchlist
Price: 9.6 USD -0.21% Market Closed
Market Cap: 17.2B USD

Operating Margin
Astellas Pharma Inc

2.1%
Current
10%
Average
6.6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
2.1%
=
Operating Profit
40.2B
/
Revenue
1.9T

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
JP
Astellas Pharma Inc
TSE:4503
2.5T JPY
2%
US
Eli Lilly and Co
NYSE:LLY
739.9B USD
40%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
375.3B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK
45%
CH
Roche Holding AG
SIX:ROG
204.9B CHF
33%
CH
Novartis AG
SIX:NOVN
190.5B CHF
33%
UK
AstraZeneca PLC
LSE:AZN
158.2B GBP
24%
US
Merck & Co Inc
NYSE:MRK
203.6B USD
34%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
11%
US
Pfizer Inc
NYSE:PFE
144.3B USD
27%

Astellas Pharma Inc
Glance View

Economic Moat
None
Market Cap
17.2B USD
Industry
Pharmaceuticals

Astellas Pharma Inc., a beacon in Japan's pharmaceutical landscape, weaves its narrative from a rich tapestry of innovation and strategic acumen. Born from the 2005 merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas quickly established itself as a global powerhouse based in Tokyo. The company operates primarily by investing heavily in R&D to drive breakthroughs in life sciences, particularly focusing on therapeutic areas like oncology, urology, immunology, and transplant-related therapies. Through these focal points, Astellas channels its resources to cultivate novel treatments that address unmet medical needs, thereby enhancing the quality of life for patients worldwide. The financial architecture of Astellas Pharma is underpinned by its strategic prowess in expanding its product pipelines and leveraging partnerships to amplify its reach. Revenue generation primarily hinges on its robust product offerings, spearheaded by successful medications such as XTANDI for prostate cancer and Prograf, which aids in organ transplantation outcomes. This diversified product portfolio is complemented by an astute approach to global market penetration, where Astellas not only markets these pharmaceuticals but also strategically collaborates with biotech firms and research institutions to harness cutting-edge technologies. This business model not only propels profitability but also ensures that Astellas remains at the forefront of medical innovation, positioning itself as a pivotal entity within the pharmaceutical industry.

ALPMY Intrinsic Value
12.71 USD
Undervaluation 24%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
2.1%
=
Operating Profit
40.2B
/
Revenue
1.9T
What is the Operating Margin of Astellas Pharma Inc?

Based on Astellas Pharma Inc's most recent financial statements, the company has Operating Margin of 2.1%.

Back to Top